Florent Cespedes analyst SOCGEN

Currently out of the existing stock ratings of Florent Cespedes, 1 are a HOLD (16.67%), 3 are a SELL (50%), 2 are a BUY (33.33%).

Florent Cespedes

Work Performance Price Targets & Ratings Chart

Analyst Florent Cespedes, currently employed at SOCGEN, carries an average stock price target met ratio of 66.67% that have a potential upside of 24.43% achieved within 460 days.

Florent Cespedes’s has documented 12 price targets and ratings displayed on 3 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on LLY, Eli Lilly and Company at 15-Feb-2023.

Wall Street Analyst Florent Cespedes

Analyst best performing recommendations are on NVO (NOVO NORDISK A/S).
The best stock recommendation documented was for NVO (NOVO NORDISK A/S) at 11/3/2020. The price target of $30.79 was fulfilled within 1 day with a profit of $0.83 (2.77%) receiving and performance score of 27.7.

Average potential price target upside

LLY Eli Lilly and Company NVS Novartis AG ADR NVO Novo Nordisk A/S

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$948

$114.51 (13.74%)

$875

9 days ago
(07-Oct-2025)

16/24 (66.67%)

$102.28 (12.09%)

541

Buy

$1023

$189.51 (22.74%)

$1135

14 days ago
(02-Oct-2025)

29/36 (80.56%)

$183.13 (21.80%)

178

Hold

$830

$-3.49 (-0.42%)

$970

1 months ago
(16-Sep-2025)

6/9 (66.67%)

$69.87 (9.19%)

106

Buy

$1050

$216.51 (25.98%)

$1100

1 months 1 days ago
(15-Sep-2025)

27/30 (90%)

$285.29 (37.31%)

272

Buy

$960

$126.51 (15.18%)

$850

4 months 12 days ago
(04-Jun-2025)

14/15 (93.33%)

$196 (25.65%)

369

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Florent Cespedes?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?